Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma

MeSH terms

• Antibodies, Monoclonal, Humanized* / administration & dosage
• Antibodies, Monoclonal, Humanized* / adverse effects
• Antineoplastic Agents, Immunological / administration & dosage
• Antineoplastic Agents, Immunological / adverse effects
• Cholagogues and Choleretics / administration & dosage
• Cholangitis, Sclerosing / immunology
• Cholangitis, Sclerosing / therapy
• Female
• Glucocorticoids / administration & dosage*
• Hepatitis* / etiology
• Hepatitis* / immunology
• Hepatitis* / therapy
• Humans
• Liver Function Tests / methods
• Melanoma* / pathology
• Melanoma* / physiopathology
• Melanoma* / therapy
• Middle Aged
• Neoplasm Staging
• Programmed Cell Death 1 Receptor / antagonists & inhibitors*
• Skin Neoplasms* / pathology
• Skin Neoplasms* / physiopathology
• Skin Neoplasms* / therapy
• Tomography, X-Ray Computed / methods
• Treatment Outcome
• Ursodeoxycholic Acid / administration & dosage